The stock has hit its daily upper limit with buying momentum still strong, even after opening at a first price of 489 yen, surpassing the offering price of 450 yen, and being listed for the first time. The company is engaged in drug discovery, and has licensing contracts for its in-house development projects with Eisai <4523> and Ohara Pharmaceutical Industries in Tokyo's Chuo Ward, as well as partnerships with Ono Pharmaceutical Industry <4528> and others in joint development projects. Despite an expected operating loss of 888 million yen for the fiscal year ending September 2024 (compared to an actual loss of 496 million yen in the previous year), revenue is expected to expand to 300 million yen, an increase of 267.8% from the previous year.
ＰＲＩＳＭＢｉｏ---ストップ高、前日上場後も買い殺到、エーザイなどとライセンスアウト契約
PRISM Bio's stock has hit the limit up, with strong buying even after its debut on the stock market. It has signed out-licensing agreements with Eisai and others.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.